A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD

Share :
Published: 13 Jun 2022
Views: 137
Rating:
Save
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy

Prof Franco Locatelli presents data from the CLIMB THAL-111 and CLIMB SCD-121 studies during a press conference at the EHA 2022 meeting.

The studies aimed to evaluate the efficacy and safety of exa-cel in 44 patients with transfusion-dependent beta-thalassemia (TDT) and 31 patients with sickle cell disease (SCD).

Read the news story here

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.